Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature.
Gynecol Oncol Rep
; 39: 100923, 2022 Feb.
Article
em En
| MEDLINE
| ID: mdl-35111894
5FU, 5-fluorouracil; CHEK2; CPS, combined positive score; EMA/CO, methotrexate, etoposide, actinomycin-D, cyclophosphamide and vincristine; FOLFOX, leucovorin (folinic acid), fluorouracil, oxaliplatin; GC, gestational choriocarcinoma; Hyperprogression; ICI, immune checkpoint inhibitor; Immunotherapy; NGC, Non-gestational choriocarcinoma; Non gestational choriocarcinoma; Pembrolizumab; TC/TE, paclitaxel/cisplatin alternating with paclitaxel/etoposide; TP53; TPS, tumor proportion score; ßhCG, beta-human chorionic gonadotropin
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Gynecol Oncol Rep
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos